* Genzyme Trangenics Corp., of Framingham, Mass.,agreed to sell G.D.R.U. Ltd., of London, to QuintilesCorp., of Research Triangle Park, N.C., for $9.5 millionin cash. The sale completes the disposition of unitsacquired from the former TSI Corp. that are outsideGenzyme Transgenics' core preclinical and nonclinicaltesting services.

* Matrix Pharmaceutical Inc., of Menlo Park, Calif., paid$2 million to repurchase U.S. and European marketingrights to its AccuSite injectable gel from U.K.-basedMedeva plc. Among the indications targeted for theproduct is treatment of genital warts, which will be thefocus of a new drug application Matrix plans to file inSeptember with the FDA.

* Neoprobe Corp., of Dublin, Ohio, sold 575,000common shares to Quantum Partners LDC at $10.50 pershare. Neoprobe's net was about $5.8 million.

* OraVax Inc., of Cambridge, Mass., completed fourearly stage clinical studies of HNK20, a monoclonalantibody being developed to prevent viral pneumonia dueto respiratory syncytial virus. No significant adversereactions were seen.

* PathoGenesis Corp., of Seattle, registered to sell 3million shares of stock in an initial public offering. Thecompany's lead drug candidates for infectious diseasesare formulations of antibiotics. It is using moleculargenetics, molecular microbiology and combinatorialchemistry in its research and development efforts relatedto pathogens in infectious diseases and discovery ofchemical compounds.

* Protein Polymer Technologies Inc., of San Diego said itentered into a potential $13 million collaboration withNew Brunswick, N.J.-based Johnson & Johnsonsubsidiary, Ethicon Inc., to develop surgical tissueadhesives and wound closure sealants. The deal includesan up-front licensing fee and equity investment totaling$3.3 million and another $10 million in milestonepayments. Protein Polymer also said its stock will resumetrading on the NASDAQ Small Cap Market under thesymbol PPTI.

(c) 1997 American Health Consultants. All rights reserved.